+91-8668442535

Freezing of Gait Treatment Market By Treatment Type (Oral Dopaminergic Medication, Wearable and Walking Aid Devices, Deep Brain Stimulation), By End User Segment (Hospitals, Clinics, Research and Academic Institutes) - Growth, Future Prospects, and Competitive Analysis, 2019 - 2027

"Freezing gait treatment market to exhibit productive growth during the forecast period." 

The global freezing of gait treatment market is growing at a CAGR of 7.2%. Globally, the increasing prevalence of Parkinson's disease has significantly increased the revenue of oral dopaminergic medications. In addition, FDA approval for new drugs and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry is driving the overall growth freezing of the gait treatment market globally. 

Market Synopsis

"Oral dopaminergic medication segment is expected to register higher growth by the end of 2027." 

Levodopa (Inbrija™, by Acorda Therapeutics) and carbidopa remain the optimum standard of symptomatic treatment for (FoG) Parkinson's disease orally. In Dec 2018, the U.S. FDA approved Inbrija™ for the alternating treatment of "OFF" incidents in people with Parkinson's disease who are already treated with levodopa/carbidopa. It is a novel approach for the treatment of OFF periods in PD. Advanced pipeline products in the wearable and walking aid segment will show promising growth in the near future. E.g., At the CES 2018 conference in Las Vegas, a Chinese company named GYENNO showcased its gait aid equipment package, which mainly helps to escape gait freeze in Parkinson's patients. Additionally, Kyungpook National University showcased an android-based gait-aid system using smart glasses with wearable sensors.

"Increasing admissions for freezing of gait in the hospital segment to witness a significant CAGR."

Increasing chronic Parkinson's disease (PD), along with significant hospital admissions internationally, are notable factors expected for the market's growth. According to FDA and other research studies, symptomatic and neuroprotective therapies are opted for PD in hospitals. In addition, deep brain stimulation procedures, along with helpful brain exercises, are also adopted in the end-user segment, showed promising results in recent times. Moreover, the increasing elderly population and admissions are escalating the growth in the end-user segment. Moreover, the lunch of new medications and equipment in the U.S. market and internationally, along with increased funding for PD patient care for the administration of freezing of gait treatment on a global scale, will drive the growth during the forecast period.

"Increasing population, new FDA approval, and the presence of top players hold the U.S. in a dominant position." 

In 2018, the U.S contributed the maximum revenue share in the freezing of the gait treatment market due to the rising prevalence of PD. Key prime factors include rising awareness about new medications and therapies, FDA approvals for new drugs, and rising PD care services along with enhanced reimbursement structure will drive the demand in the near future. In addition, emerging nations always suffer the burden of chronic diseases. Nevertheless, there is no significant treatment targeted towards freezing of gait in PD, but strong pipeline drugs and products, along with the approval for levodopa, will further enhance the growth on a global scale. 

"Increased research and development with strong product pipelines in the developed regions" 

Major players in the freezing of gait treatment market are Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland, Galway (NUI Galway), Kyungpook National University, Republic of Korea, MedEXO Robotics, TABLE Teva Pharmaceuticals, and others. In addition, major organizations and research centers are developing progressive technologies with new technology expansion in the wearable and walking aids systems, electronic brain implants, and other stimulators for freezing gait treatment on a global scale.

Historical & Forecast Period

This study report represents an analysis of each segment from 2017 to 2027, considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027.

 

Segmentation Treatment Type (2017–2027; US$ Mn)

 • Oral Dopaminergic Medication (Inbrija - levodopa inhalation powder)

 • Wearable and Walking Aid Devices

 • Deep Brain Stimulation

 • Others (Brain Implants)

 

End-User Segment (2017–2027; US$ Mn)

 • Hospitals

 • Clinics

 • Research and Academic Institutes

 

Geography Segment (2017–2027; US$ Mn)

 • North America (U.S., Canada)

 • Europe (U.K., Germany, Rest of Europe)

 • Asia Pacific (Japan, China, Rest of Asia Pacific)

 • Latin America (Brazil, Mexico, Rest of Latin America)

 • Middle East & Africa (GCC, Rest of the Middle East & Africa)

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better market understanding of the overall freezing of the gait treatment market. The global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolio, and business strengths.

Frequently asked questions :

The market for Freezing of Gait Treatment Market is expected to reach US$ XX Bn by 2027.

The Freezing of Gait Treatment Market is expected to see significant CAGR growth over the coming years, at 7.2%.

The report is forecasted from 2018-2027.

The base year of this report is 2021.

Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland, Galway (NUI Galway), Kyungpook National University, Republic of Korea, MedEXO Robotics are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59720
Report Format:   PDF
Pages:   120
Rating:    4.4 (58)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support